Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes

References

• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiat 2007;164(6):942-8
   PubMed Web of Science ®Google Scholar
• Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adoles Health 2004;35(4):346.e1-9
   Google Scholar
• Barkley RA, Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adoles Psych 2010;49(5):503-13
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the united states: results from the national comorbidity survey replication. Am J Psychiat 2006;163(4):716-23
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Ostergaard SD, Leckman JF, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015. [Epub ahead of print]
   Google Scholar
• Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev 2007;39(1):94-105
   Google Scholar
• Cortese S, Ramos Olazagasti MA, Klein RG, et al. Obesity in men with childhood ADHD: a 33-year controlled, prospective, follow-up study. Pediatrics 2013;131(6):e1731-8
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012;69(12):1295-303
   PubMed Web of Science ®Google Scholar
• Ramos Olazagasti MA, Klein RG, Mannuzza S, et al. Does childhood attention-deficit/hyperactivity disorder predict risk-taking and medical illnesses in adulthood? J Am Acad Child Adolesc Psychiatry 2013;52(2):153-162.e4
   PubMed Web of Science ®Google Scholar
• Coghill D, Markarian M, Seth S. Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD clinical care pathway. Child and Adolesc Psychiatry Mental Health; in press
   Google Scholar
• Langley K, Fowler T, Ford T, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry 2010;196(3):235-40
   PubMed Web of Science ®Google Scholar
• Fredriksen M, Halmoy A, Faraone SV, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol 2013;23(6):508-27
   PubMed Web of Science ®Google Scholar
• Bihlar Muld B, Jokinen J, Bolte S, Hirvikoski T. Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study. J Subst Abuse Treat 2015;51:82-90
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Eng J Med 2012;367(21):2006-14
   PubMed Web of Science ®Google Scholar
• Man KK, Chan EW, Coghill D, et al. Methylphenidate and the risk of trauma. Pediatrics 2015;135(1):40-8
   Google Scholar
• Raman SR, Marshall SW, Haynes K, et al. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Inj Prev 2013;19(3):164-70
   Web of Science ®Google Scholar
• Dalsgaard S, Nielsen HS, Simonsen M. Consequences of ADHD medication use for children’s outcomes. J Health Econ 2014;37:137-51
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA cooperative group. multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999;56(12):1073-86
   PubMed Web of Science ®Google Scholar
• Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011;11:176
   PubMed Web of Science ®Google Scholar
• Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008;28(3):S46-53
   Google Scholar
• Coghill D, Banaschewski T, Lecendreux M, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2013;23(10):1208-18
   PubMed Web of Science ®Google Scholar
• Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 2014;53(2):174-87
   PubMed Web of Science ®Google Scholar
• Savill NC, Buitelaar JK, Anand E, et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS Drugs 2015;29(2):131-51
   PubMed Web of Science ®Google Scholar
• Ruggiero S, Clavenna A, Reale L, et al. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014;24(10):1578-90
   Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with pediatrics. ADHD 2011;127(6):e1406-13
   Google Scholar
• Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther 2012;29(5):385-400
   PubMed Web of Science ®Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010;19(4):353-64
   PubMed Web of Science ®Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53(2):153-73
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15(8):476-95
   PubMed Web of Science ®Google Scholar
• Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011;25(2):157-69
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24(1):24-9
   PubMed Web of Science ®Google Scholar
• Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs 2010;24(10):843-66
   Google Scholar
• Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 2009;50(3):335-42
   PubMed Web of Science ®Google Scholar
• O’Connor BC, Garner AA, Peugh JL, et al. Improved but still impaired: symptom-impairment correspondence among youth with attention-deficit hyperactivity disorder receiving community-based care. J Dev Behav Pediatr 2015;36(2):106-14
   PubMed Web of Science ®Google Scholar
• Epstein JN, Langberg JM, Lichtenstein PK, et al. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Arch Pediatr Adolesc Med 2010;164(2):160-5
   PubMed Web of Science ®Google Scholar
• Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Therapeut 2006;28(11):1892-908
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Shockey E, Davies M, et al. Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003;42(6):627-33
   PubMed Web of Science ®Google Scholar
• Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008;22(3):213-37
   PubMed Web of Science ®Google Scholar
• Coghill DR, Seth S, Pedroso S, et al. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry 2014;76(8):603-15
   PubMed Web of Science ®Google Scholar
• Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci Biobehav Rev 2010;34(8):1256-66
   PubMed Web of Science ®Google Scholar
• Coghill D. Editorial: Acknowledging complexity and heterogeneity in causality--implications of recent insights into neuropsychology of childhood disorders for clinical practice. J Child Psychol Psychiatry 2014;55(7):737-40
   Google Scholar
• Coghill DR, Hayward D, Rhodes SM, et al. A longitudinal examination of neuropsychological and clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): improvements in executive functioning do not explain clinical improvement. Psychol Med 2014;44(5):1087-99
   PubMed Web of Science ®Google Scholar
• Coghill DR, Seth S, Matthews K. A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. Psychol Med 2014;44(9):1989-2001
   PubMed Web of Science ®Google Scholar
• Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry 2005;57(11):1224-30
   PubMed Web of Science ®Google Scholar
• Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 2005;57(11):1336-46
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke E, Bitsakou P, Thompson M. Beyond the dual pathway model: evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010;49(4):345-55
   PubMed Web of Science ®Google Scholar
• Conners CK. Conners’ rating scales-revised user’s manual. Multi-Health Systems. Multi-Health Systems, Inc., North Tonawanda, NY; 1997
   Google Scholar
• Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol 2003;28(8):559-67
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Feurer ID, Hannah JN, et al. Obtaining systematic teacher reports of disruptive behavior disorders utilizing DSM-IV. J Abnorm Child Psychol 1998;26(2):141-52
   Google Scholar
• DuPaul GJ. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. 1998: Guilford Press
   Google Scholar
• Swanson JM, Nolan W, Pelham WE. The SNAP-IV rating scale. 1992. Available from: http://www.adhd.net
   Google Scholar
• DuPaul GJ, Barkley RA. Situational variability of attention problems: psychometric properties of the revised home and school situations questionnaires. J Clin Child Psychol 1992;21(2):178-88
   Web of Science ®Google Scholar
• Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003;42(9):1015-37
   PubMed Web of Science ®Google Scholar
• Pelham WEJr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol 2005;34(3):449-76
   PubMed Web of Science ®Google Scholar
• Weckerly J, Aarons GA, Leslie LK, et al. Attention on inattention: the differential effect of caregiver education on endorsement of ADHD symptoms. J Dev Behav Pediatr 2005;26(3):201-8
   PubMedGoogle Scholar
• European Medicines Agency (EMA). C.f.M.P.f.H.U.C. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). 2009
   Google Scholar
• European Medicines Agency (EMA). C.f.M.P.f.H.U.C, Guideline on clinical investigation of medicinal products, including depot preparations, in the treatment of schizophrenia. 2012
   Google Scholar
• European Medicines Agency (EMA). C.f.M.P.f.H.U.C, Guideline on clinical investigation of medicinal products in the treatment of depression. 2013
   Google Scholar
• European Medicines Agency (EMA). C.f.M.P.f.H.U.C, Draft concept paper on the development of medicinal products for the treatment of autism spectrum disorder. 2013
   Google Scholar
• Döpfner M, Steinhausen HC, Coghill D, et al. Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. Eur Child Adolesc Psychiatry 2006;15(1):i46-55
   PubMedGoogle Scholar
• Group, MC. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA cooperative group. multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999;56(12):1073-86
   Google Scholar
• Valo S, Tannock R. Diagnostic instability of DSM–IV ADHD subtypes: effects of informant source, instrumentation, and methods for combining symptom reports. J Clin Child Adolesc Psychol 2010;39(6):749-60
   PubMed Web of Science ®Google Scholar
• Shemmassian SK, Lee SS. Comparing four methods of integrating parent and teacher symptom ratings of attention-deficit/hyperactivity disorder (ADHD). J Psychopathol Behav Assess 2012;34(1):1-10
   Google Scholar
• Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998;59(7):24-30
   Google Scholar
• Waschbusch DA, Pelham WEJr, Waxmonsky J, Johnston C. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder? J Dev Behav Pediatr 2009;30(2):158-68
   PubMed Web of Science ®Google Scholar
• Pelham WE, Waxmonsky JG, Schentag J, et al. Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting. J Atten Disord 2011;15(1):28-35
   Google Scholar
• Swanson JM, Lerner M, Wigal T, et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 2002;6(Suppl 1):S73-88
   PubMedGoogle Scholar
• Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60
   PubMedGoogle Scholar
• Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34(1):47-53
   PubMedGoogle Scholar
• Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry 2002;181:416-21
   PubMed Web of Science ®Google Scholar
• Coghill D, Spiel G, Baldursson G, et al. Which factors impact on clinician-rated impairment in children with ADHD? Eur Child Adolesc Psychiatry 2006;15(1):I30-7
   Google Scholar
• Breuer D, Gortz-Dorten A, Rothenberger A, Dopfner M. Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. Eur Child Adolesc Psychiatry 2011;20(Suppl 2):S289-96
   Google Scholar
• Childress AC, Arnold V, Adeyi B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord 2014;18(2):123-32
   Google Scholar
• Rosler M, Retz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 2010;11(5):709-18
   PubMed Web of Science ®Google Scholar
• Stringaris A, Goodman R, Ferdinando S, et al. The Affective Reactivity Index: a concise irritability scale for clinical and research settings. J Child Psychol Psychiatry 2012;53(11):1109-17
   PubMed Web of Science ®Google Scholar
• De Crescenzo F, Armando M, Mazzone L, et al. The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis. Atten Defic Hyperact Disord 2014;6(1):49-58
   Google Scholar
• Tabori-Kraft J, Sorensen MJ, Kaergaard M, et al. Is OPTAx useful for monitoring the effect of stimulants on hyperactivity and inattention? A brief report. Eur Child Adolesc Psychiatry 2007;16(5):347-51
   Google Scholar
• Ramos-Quiroga JA, Casas M. Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs 2011;25(1):17-36
   Google Scholar
• Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Cons Clin Psychol 1991;59(1):12-19
   PubMed Web of Science ®Google Scholar
• Dittmann RW, Cardo E, Nagy P, et al. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs 2014;28(11):1059-69
   PubMed Web of Science ®Google Scholar
• Soutullo C, Banaschewski T, Lecendreux M, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 2013;27(9):743-51
   PubMed Web of Science ®Google Scholar
• Erder MH, Xie J, Signorovitch JE, et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy 2012;10(6):381-95
   PubMedGoogle Scholar
• Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;62(9):954-62
   PubMed Web of Science ®Google Scholar
• Coghill DR, Banaschewski T, Lecendreux M, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry 2014;53(6):647-657 e1
   PubMed Web of Science ®Google Scholar
• Arnold LE, Lindsay RL, Conners CK, et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2004;14(4):542-54
   PubMedGoogle Scholar
• Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007;61(5):694-9
   PubMedGoogle Scholar
• Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43(7):896-904
   PubMedGoogle Scholar
• Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. Prim Care Companion CNS Disord 2012;14(6):11r01336
   Google Scholar
• European Medicines Agency (EMA). C.f.M.P.f.H.u.C. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). 2010. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf
   Google Scholar
• Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36(7):980-8
   PubMed Web of Science ®Google Scholar
• Berk M, Ng F, Dodd S, et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract 2008;14(6):979-83
   PubMed Web of Science ®Google Scholar
• Shaffer D, Gould MS, Brasic J, et al. A children’s global assessment scale (CGAS). Arch Gen Psychiatry 1983;40(11):1228-31
   PubMed Web of Science ®Google Scholar
• Bird HR, Canino G, Rubio-Stipec M, Ribera JC. Further measures of the psychometric properties of the children’s global assessment scale. Arch Gen Psychiatry 1987;44(9):821-4
   Google Scholar
• Bird HR, Shaffer D, Fisher P, et al. The Columbia Impairmenr Scale (CIS): pilot findings on a measure of global impairment for children and adolescents. J Method Psychiatr Res 1993;3:167-76
   Web of Science ®Google Scholar
• Bird HR, Andrews H, Schwab-Stone M, et al. Global measures of impairment for epidemiologic and clinical use with children and adolescents. J Method Psychiatr Res 1996;6:295-307
   Web of Science ®Google Scholar
• Hodges K, Doucette-Gates A, Liao Q. The relationship between the child and adolescent functional assessment scale (CAFAS) and indicators of functioning. J Child Family Stud 1999;8:108-22
   Google Scholar
• Maziade M, Rouleau N, Lee B, et al. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol 2009;19(6):709-18
   Google Scholar
• Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol 2011;21(6):581-8
   PubMed Web of Science ®Google Scholar
• (CADDRA), C.A.D.H.D.R.A. Canadian ADHD Practice Guidelines. 3rd editon, ed. CADDRA, Toronto; 2011
   Google Scholar
• Fuentes J, Danckaerts M, Cardo E, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2013;33(6):766-74
   Google Scholar
• Banaschewski T, Soutullo C, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs 2013;27(10):829-40
   PubMed Web of Science ®Google Scholar
• Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch Pediatr Adolesc Med 2002;156(4):384-91
   Google Scholar
• Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol 2013;23(6):528-33
   PubMed Web of Science ®Google Scholar
• Riley AW, Lyman LM, Spiel G, et al. The family strain index (FSI). Reliability, validity, and factor structure of a brief questionnaire for families of children with ADHD. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):I72-8
   Google Scholar
• Saylor K, Buermeyer C, Sutton V, et al. The life participation scale for attention-deficit/hyperactivity disorder–child version: psychometric properties of an adaptive change instrument. J Child Adolesc Psychopharmacol 2007;17(6):831-42
   Google Scholar
• Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114(1):e1-8
   PubMed Web of Science ®Google Scholar
• Hoza B, Pelham WEJr, Dobbs J, et al. Do boys with attention-deficit/hyperactivity disorder have positive illusory self-concepts? J Abnorm Psychol 2002;111(2):268-78
   PubMed Web of Science ®Google Scholar
• Shaffer D, Fisher P, Lucas CP, et al. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 2000;39(1):28-38
   PubMed Web of Science ®Google Scholar
• Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010;19(2):83-105
   PubMed Web of Science ®Google Scholar
• WHO. The world health organization quality of life assessment (WHOQOL): position paper from the world health organization. Soc Sci Med 1995;41(10):1403-9
   Google Scholar
• Rentz AM, Matza LS, Secnik K, et al. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res 2005;14(3):719-34
   PubMed Web of Science ®Google Scholar
• Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with Attention-Deficit/Hyperactivity Disorder: a population-based study. Health Qual Life Outcomes 2006;4:26
   PubMed Web of Science ®Google Scholar
• Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39(8):800-12
   PubMed Web of Science ®Google Scholar
• Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005;116(3):e364-9
   PubMed Web of Science ®Google Scholar
• Coghill D, Hodgkins P. Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. Eur Child Adolesc Psychiatry 2009; in press
   Google Scholar
• Riley AW, Coghill D, Forrest CB, et al. Validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):I63-71
   Google Scholar
• Kamp-Becker I, Schroder J, Muehlan H, et al. Health-related quality of life in children and adolescents with autism spectrum disorder. Z Kinder Jugendpsychiatr Psychother 2011;39(2):123-31
   Google Scholar
• Cavanna AE, David K, Bandera V, et al. Health-related quality of life in Gilles de la Tourette syndrome: a decade of research. Behav Neurol 2013;27(1):83-93
   Google Scholar
• Jardine J, Glinianaia SV, McConachie H, et al. Self-reported quality of life of young children with conditions from early infancy: a systematic review. Pediatrics 2014;134(4):e1129-48
   PubMed Web of Science ®Google Scholar
• Lin YF, Chung HH. Parenting stress and parents’ willingness to accept treatment in relation to behavioral problems of children with attention-deficit hyperactive disorder. J Nurs Res 2002;10(1):43-56
   Google Scholar
• Xiang YT, Luk ES, Lai KY. Health-related quality of life in children and adolescents with autism spectrum disorder. Z Kinder Jugendpsychiatr Psychother 2011;43(8):731-8
   Google Scholar
• Riley AW, Spiel G, Coghill D, et al. Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 2006;15(1):I38-45
   Google Scholar
• Marques JC, Oliveira JA, Goulardins JB, et al. Comparison of child self-reports and parent proxy-reports on quality of life of children with attention deficit hyperactivity disorder. Health Qual Life Outcomes 2013;11:186
   Google Scholar
• Coghill D. Pragmatic measures in paediatric psychopharmacology-are we getting it right? Eur Neuropsychopharmacol 2011;21(8):571-83
   Google Scholar
• Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs 2014;28(12):1191-203
   PubMed Web of Science ®Google Scholar
• Childress AC, Cutler AJ, Saylor K, et al. Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2014;24(4):210-17
   PubMed Web of Science ®Google Scholar
• Altin M, El-Shafei AA, Yu M, et al. Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries. Drugs Context 2013;2013:212260
   Google Scholar
• Ghanizadeh A, Sayyari Z, Mohammadi MR. Effect of methylphenidate and folic Acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial. Iran J Psychiatry 2013;8(3):108-12
   Google Scholar
• Haertling F, Mueller BO. Bilke-hentsch, effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin LA) in school children under daily practice conditions. Atten Defic Hyperact Disord 2014. [Epub ahead of print]
   Google Scholar
• Brod M, Adler LA, Lipsius S, et al. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA. Atten Defic Hyperact Disord 2015 [Epub ahead of print]
   Google Scholar
• Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47(9):994-1009
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Kvist AP, Leckman JF, et al. Cardiovascular safety of stimulants in children with Attention-Deficit/Hyperactivity Disorder: A nationwide prospective cohort study. J Child Adolesc Psychopharmacol 2014;24(6):302-10
   PubMed Web of Science ®Google Scholar
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Eng J Med 2011;365(20):1896-904
   PubMed Web of Science ®Google Scholar
• Cortese S, Holtmann M, Banaschewski T, et al. European ADHD Guidelines Group, Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54(3):227-46
   PubMed Web of Science ®Google Scholar
• Graham J, Banaschewski T, Buitelaar J, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20(1):17-37
   Google Scholar
• Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011;50(10):978-90
   PubMed Web of Science ®Google Scholar
• Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20(2):109-17
   PubMed Web of Science ®Google Scholar
• Mullins D, Pfefferbaum B, Schultz H, Overall JE. Brief psychiatric rating scale for children: quantitative scoring of medical records. Psychiatry Res 1986;19(1):43-9
   Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9
   Web of Science ®Google Scholar
• Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22(2):343-81
   PubMedGoogle Scholar
• Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86(2):184-92
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJ, Coghill D, Wigal T, et al. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009;19(6):683-90
   Google Scholar
• Frazier TW, Demaree HA, Youngstrom EA. Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder. Neuropsychology 2004;18(3):543-55
   PubMed Web of Science ®Google Scholar
• Jepsen JR, Fagerlund B, Mortensen EL. Do attention deficits influence IQ assessment in children and adolescents with ADHD? J Atten Disord 2009;12(6):551-62
   Google Scholar
• Gimpel GA, Collett BR, Veeder MA, et al. Effects of stimulant medication on cognitive performance of children with ADHD. Clin Pediatr 2005;44(5):405-11
   Google Scholar
• Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54(9):857-64
   PubMedGoogle Scholar
• Tsai CS, Huang YS, Wu CL, et al. Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder. BMC Psychiatry 2013;13:330
   Google Scholar
• van Lieshout M, Luman M, Buitelaar J, et al. Does neurocognitive functioning predict future or persistence of ADHD? A systematic review. Clin Psychol Rev 2013;33(4):539-60
   PubMed Web of Science ®Google Scholar
• Biederman J, Monuteaux MC, Doyle AE, et al. Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Cons Clin Psychol 2004;72(5):757-66
   PubMed Web of Science ®Google Scholar
• Wahlstedt C, Thorell LB, Bohlin G. Heterogeneity in ADHD: neuropsychological pathways, comorbidity and symptom domains. J Abnorm Child Psychol 2009;37(4):551-64
   PubMed Web of Science ®Google Scholar
• Gualtieri C.T, Johnson LG. Medications do not necessarily normalize cognition in ADHD patients. J Atten Disord 2008;11(4):459-69
   PubMed Web of Science ®Google Scholar
• Bedard AC, Stein MA, Halperin JM, et al. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry 2015;56(1):40-8
   Google Scholar
• Cortese S, Ferrin M, Brandeis D, et al. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 2015;54(3):164-74
   PubMed Web of Science ®Google Scholar
• Morris RC, Evendon JL, Sahakian BJ, Robbins TW. In cognitive neurochemistry. In: Stahl SM, Iverson SD, Goodman EC, Computer-aided assessment of dementia: comparative studies of neuropsychological deficits in Alzheimer-type dementia and Parkinson’s disease. Oxford University Press, Oxford; 1987. pp 21-36
   Google Scholar
• Gioia GA, Isquith PK, Guy SC, et al. BRIEF: behavior rating inventory of executive function: professional manual. Psychol Assess Res 2000
   Google Scholar
• Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med 2010;122(5):42-51
   PubMed Web of Science ®Google Scholar
• Findling RL, Adeyi B, Dirks B, et al. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate. J Child Adolesc Psychopharmacol 2013;23(1):28-35
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 2004;161(7):1173-80
   Google Scholar
• Douglas VI, Barr RG, Desilets J, Sherman E. Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1995;34(7):877-85
   Web of Science ®Google Scholar
• Andersen SL, Napierata L, Brenhouse HC, Sonntag KC. Juvenile methylphenidate modulates reward-related behaviors and cerebral blood flow by decreasing cortical D3 receptors. Eur J Neurosci 2008;27(11):2962-72
   Google Scholar
• Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977;198(4323):1274-6
   PubMed Web of Science ®Google Scholar
• Tannock R, Schachar R. Methylphenidate and cognitive perseveration in hyperactive children. J Child Psychol Psychiatry 1992;33(7):1217-28
   PubMed Web of Science ®Google Scholar
• Funk JB, Chessare JB, Weaver MT, Exley AR. Attention deficit hyperactivity disorder, creativity, and the effects of methylphenidate. Pediatrics 1993;91(4):816-19
   Google Scholar